Neopharm Co., Ltd. (092730) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Neopharm Co., Ltd. (092730:KRX), powered by AI.

Current Price
₩17,600
P/E Ratio
10.1
Market Cap
282.1B
Sector
Common Stock
What is the Neopharm Co., Ltd. stock price forecast?

Neopharm Co., Ltd. is currently trading at ₩17,600. View real-time AI analysis on Alpha Lenz.

What is Neopharm Co., Ltd. insider trading activity?

View the latest insider trading data for Neopharm Co., Ltd. on Alpha Lenz.

What is Neopharm Co., Ltd.'s P/E ratio?

Neopharm Co., Ltd.'s P/E ratio is 10.1.

Neopharm Co., Ltd.

KRX · 092730
₩17,600+700(+4.14%)Market closedKRX regular session 09:00–15:30 KST
Ask about Neopharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Neopharm Co., Ltd. trades at a P/E of 10.1 (undervalued) with solid ROE of 14.9%. 3Y revenue CAGR of 15.8% highlights clear growth momentum.

Ask for details

Company Overview

Neopharm Co., Ltd. is a prominent player in the biotechnology sector, specializing in the development and production of innovative skincare and dermatology products. The company's primary focus is on advancing skin barrier technologies that cater to a wide range of dermatological needs. Neopharm leverages its cutting-edge research and development capabilities to create a diverse portfolio of products aimed at improving skin health and treating various dermatological conditions. Key industries impacted by Neopharm's offerings include healthcare, pharmaceuticals, and cosmetics, reflecting its unique positioning at the intersection of therapeutic and cosmetic skincare solutions. Neopharm Co., Ltd. is recognized for its commitment to quality and innovation, continuously driving advancements in skin science. Within the financial markets, Neopharm's contributions to the skincare and biotech fields underscore its relevance, appealing to investors interested in companies that blend scientific research with practical health applications. Established in an era of growing awareness around skincare, Neopharm Co., Ltd. plays a vital role in meeting the increasing global demand for effective and scientifically-backed skincare solutions.

CEO김양수
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩282,092,606,400Market Cap
₩132,184,096,280Revenue
16.03MShares Out
0Employees

Margins

65.36%Gross
26.90%EBITDA
21.77%Operating
24.41%Pre-Tax
21.05%Net

Valuation

10.14P/E
1.44P/B
2.13EV/Sales
7.23EV/EBITDA
10.45P/FCF

Growth (CAGR)

15.84%Rev 3Yr
10.12%Rev 5Yr
10.31%Op Inc 3Yr
5.61%Op Inc 5Yr
17.78%Net Inc 3Yr
8.94%Net Inc 5Yr

Returns

13.56%ROA
14.95%ROE
15.75%ROIC

Financial Health

₩26,824,586,080Cash & Cash Equivalents
₩-4,370,276,330Net Debt
11.49%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Neopharm Co., Ltd. (ticker: 092730) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $282.1B.

The current price is ₩17,600 with a P/E ratio of 10.14x and P/B of 1.44x.

ROE is 14.95% and operating margin is 21.77%. Annual revenue is $132.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Neopharm Co., Ltd. (092730) Stock Forecast 2026 ₩17,600 — Price, Financials & Analyst Targets | Alpha Lenz